Interesting RLAY Call Options For February 2026

Relay Therapeutics (RLAY) is trading at $8.74 and the February 2026 $9.00 call is bid at $0.10; selling that covered call would commit the seller to sell at $9 and produce a 4.12% total return if assigned. The premium alone is a 1.14% immediate boost (6.96% annualized YieldBoost) while the option’s implied volatility is 137% versus a trailing 12‑month volatility of 76%, and analytics place the probability the contract expires worthless at 36%, highlighting both income potential and the risk of ceding upside if the stock rallies.

Analysis

Market structure: Short-dated-to-long-dated options market and covered-call sellers are the direct beneficiaries — they collect the $0.10 premium and can generate a 1.14% absolute (6.96% annualized) YieldBoost to equity returns if the Feb‑2026 $9 call expires worthless. losers are holders seeking unlimited upside: with RLAY at $8.74 and a $9 strike, assignment probability (~64%) and high implied volatility (137% vs realized 76%) mean option-driven selling/hedging flows can compress upside and amplify intraday moves.

Risk assessment: Tail risks include a clinical trial or FDA setback that can wipe out >70% of market cap for a small biotech (immediate to weeks), or an unexpected secondary offering that dilutes shareholders (months). In the near term (days–weeks) option-hedge gamma can create sharp price moves around headlines; medium term (3–12 months) cash runway, upcoming readouts, or financing needs are key drivers that will recalibrate IV toward realized volatility.

Trade implications: IV is >60 pts rich vs realized, so naked long-vol is expensive; prefer premium-selling strategies if you can own the stock (cash-secured). For directional exposure, size equity positions small (1–3% portfolio) and use covered calls or cash-secured puts to monetize elevated IV while accepting assignment risk; avoid buying calls/straddles until IV compresses below ~100% or a clear catalyst emerges.

Contrarian angles: Consensus treats the $9 call as a low-premium income trade, but the market is pricing a ~64% assignment risk — that asymmetry favors disciplined option sellers with capital to take stock on assignment. Historical biotech patterns show IV mean reversion after negative catalysts; if no bad news within 3–6 months IV can collapse and premium sellers who get long stock early will outperform outright call buyers.

Key Decisions for Investors

• Establish a small, income-oriented position: buy RLAY up to $8.74 and sell-to-open Feb‑2026 $9 calls for $0.10 (covered-call). Size 1–2% of portfolio; target total return to assignment 4.12%. If RLAY falls below $6.55 (≈25% drop) close/roll the covered call to limit drawdown.
• Execute a cash-secured put instead of long calls: sell Feb‑2026 $7.00 cash‑secured puts (if premium ≥$0.30) to collect yield and set effective entry ≤$6.70. Close the put if implied vol compresses >40% or company announces a positive Phase readout.
• Relative-value pair: go long RLAY equity (0.5–1% portfolio) vs short biotech ETF IBB (notional matched to RLAY historical beta) to isolate idiosyncratic upside over 3–12 months around expected catalysts; trim if RLAY outperforms by >30% or IV falls below 100%.
• Avoid buying calls/straddles on RLAY while IV >120%. If needing convex upside, use calendar spreads (sell Feb‑2026 short-dated call against longer-dated call) to harvest elevated near-term IV and limit theta decay; enter when front-month IV > mid/long-term IV by ≥20 pts.